PRTC PureTech Health plc
$17.42▲ +0.99%
Unknown
Other
Volume 6.8K
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
$424.03M
P/E Ratio
–
Div Yield
–%
52W Range
14.50 - 19.92
% vs 50 MA
0.02%
% vs 200 MA
0.75%
RSI-14
50.6
MACD Histogram
-0.0900
Beta (1Y vs SPY)
0.71
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Business Wire · Sep 9, 2026 5:13 PM
PureTech Health: Notice of Half-Yearly Results
Business Wire · Sep 4, 2026 6:00 AM
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
Business Wire · Aug 25, 2026 11:05 AM
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress
Business Wire · Aug 25, 2026 11:00 AM
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · Jul 13, 2026 6:00 AM
Celea Therapeutics secures $180m for Phase III SURPASS-IPF trial
Clinical Trials Arena · Jul 3, 2026 11:06 AM
A PureTech startup banks $180M for a new IPF drug
BioPharma Dive · Jul 2, 2026 11:04 AM
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · Jul 2, 2026 6:01 AM
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Business Wire · Jul 2, 2026 6:01 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
No Reddit posts found for PRTC.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.